Skip to content

White paper:
The Rescheduling Shuffle

At some point in the first half of 2024, there’s a strong chance that cannabis will be reclassified as a Schedule III controlled substance from a Schedule I controlled substance, as defined by the Controlled Substances Act.

The ripple effects of such a decision at the federal level could be enormous.  
And extensive. 

To address the possibilities—and offset speculation from all sides of the issue, our white paper, The Rescheduling Shuffle, addresses: 

  • What’s driving this reclassification initiative  
  • How the shift to Schedule III could play out 
  • Potential pros and cons of the possible rescheduling 
  • The path forward for federal enforcement efforts 
  • Our thinking around the potential ripple effects 

Access report



Information contained herein is intended solely for informational purposes and should not be interpreted as a recommendation, offer, or solicitation of securities. Investing involves risk up to and including the loss of principal. Past performance is not indicative of future results. Prospective investors should seek the advice of their financial, legal, and tax advisors before making any investment decisions.